Research Papers:

Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens

Kamala Vanarsa, Shereen Enan, Pooja Patel, Briony Strachan, Anto Sam Crosslee Louis Sam Titus, Aphrihl Dennis, Yair Lotan and Chandra Mohan _

PDF  |  Full Text  |  Supplementary Files  |  How to cite  |  Press Release

Oncotarget. 2021; 12:783-790. https://doi.org/10.18632/oncotarget.27941

Metrics: PDF 1124 views  |   Full Text 4865 views  |   ?  


Kamala Vanarsa1, Shereen Enan1, Pooja Patel1, Briony Strachan1, Anto Sam Crosslee Louis Sam Titus1, Aphrihl Dennis2, Yair Lotan2 and Chandra Mohan1

1 Department Biomedical Engineering, University of Houston, Houston, TX, USA

2 Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA

Correspondence to:

Chandra Mohan,email: [email protected]

Keywords: urothelial; proteomics; targeted screens; interleukins; inflammation

Received: November 13, 2020     Accepted: March 25, 2021     Published: April 13, 2021

Copyright: © 2021 Vanarsa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Purpose: The purpose of this study is to identify novel urine protein biomarkers of bladder cancer using a Luminex based screening platform.

Materials and Methods: The current study examines urine samples from 66 subjects, comprised of 31 Urology clinic controls and 35 bladder cancer patients, using a Luminex based screening platform. ELISA validation was carried out for the top 4 prospective urine biomarkers using an independent cohort of 20 Urology clinic controls and 60 bladder cancer (BC) subjects.

Results: Of the 16 proteins screened by Luminex, 10 showed significant elevation in BC compared to the controls. Eight of these urine proteins were able to differentiate BC from control urine with ROC AUC values exceeding 0.70 at p < 0.0001, with specificity values exceeding 0.9. Upon ELISA validation, urine IL-1α, IL-1ra, and IL-8 were able to distinguish control urine from urine drawn from various bladder cancer stages, with IL-8 being the best discriminator. Compared to members of the IL-1 cytokine family, urine IL-8 was also best at discriminating T1 and/or T2–T4 from Ta BC (ROC AUC ≥ 0.83), as well as high grade from low grade BC (ROC AUC ≥ 0.82).

Conclusions: These findings suggest that urine IL-1α, IL-1ra and IL-8 are useful indicators of bladder cancer. Urine IL-8 not only distinguishes bladder cancer from controls, it also discriminates high grade from low grade disease, and the successive clinical stages of bladder cancer. While supportive of previous reports, these findings warrant further analysis in prospective cohorts.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27941